Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 14/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014679 | 0.93 | LCK (0.74) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7026453 | 0.92 | LCK (0.73) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7589531 | 0.90 | LCK (0.71) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7014906 | 0.90 | LCK (0.71) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7019928 | 0.90 | LCK (0.72) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7024707 | 0.89 | LCK (0.71) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7021617 | 0.88 | LCK (0.70) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7014887 | 0.88 | LCK (0.69) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7023052 | 0.87 | LCK (0.80) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7018074 | 0.86 | LCK (0.65) | LCKJAK2JAK3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |